Skip to NavigationSkip to content

cardiovascular

AZ's Farxiga reduces major adverse cardiovascular event risk in type 2 diabetes, new data shows

AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing the drug’s efficacy in reducing the relative risk of major adverse cardiovascular events (MACE) in patients with type-2 diabetes (T2D) who had a prior heart attack.

Findings from a pre-specified sub-analysis indicated that the therapy reduced the risk of MACE by 16% compared to placebo, and also reduced the relative risk of hospitalisation for heart failure (hHF) in T2D patients regardless of their ejection fraction (EF) stat

Sanofi and Regeneron's Praluent approved in Europe to reduce CV risk

Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to reduce cardiovascular risk in patients with established atherosclerotic CV disease (ASCVD) by lowering low-density lipoprotein cholesterol (LDL-C) levels as an adjunct to correction of other risk factors.

ASCVD refers to a build-up of plaque in the arteries which can reduce blood flow and lead to a range of conditions including peripheral artery disease, acute coronary syndrome (ACS) and stroke.

FDA approve valsartan generic after shortages of supply

The FDA has approved a new generic version of blood pressure drug valsartan. The approval comes amid shortages in supply after recalls were made in reaction to the discovery of impurities.The generic version will be produced by Mumbai-based firm Alkem Laboratories Limited.

The F.D.A. prioritized the review of this drug application to help relieve the recent shortage of this critical medicine as a result of multiple recalls of generic valsartan products from several manufacturers,” the agency said in a statement.

Novartis' Entresto tops enalapril in stabilised heart failure patients

Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association's (AHA) scientific sessions, showing that the drug proved itself superior to enalapril-a in patients with heart failure with reduced ejection fraction (HFrEF) who had been stabilised following hospitalisation for an acute decompensation heart failure (ADHF) event.

AZ's Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study

AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart Association (AHA) Scientific Sessions 2018 in Chicago, showing that the drug “significantly reduced” hospitalisation or death arising from cardiovascular (CV) conditions in a broad patient population.

The findings were derived from the DECLARE trial, the largest SGLT2 inhibitor CV outcomes study ever conducted, encompassing more than 17,000 participants.

Researchers design new class of drugs to counter cardiovascular disease

Cleveland Clinic researchers have designed a potential new class of drugs that may reduce the risk of cardiovascular disease by targeting a microbial pathway in the gut; a study published in Nature Medicine has shown.

The study, which took place in mice, demonstrated that the new drugs reversed two major risk factors for cardiovascular disease.

The new and improved Spring 2018 edition of Pharmafile is available to read online now!

The Spring 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in the pharmaceutical and life sciences industries, is now available to read online.

Google develops AI to predict cardiovascular risk

Google and Verily Life Sciences, a subsidiary within Alphabet, focused on developing health-tech, have revealed the fruits of a combined effort to harness AI to provide tools to healthcare professionals.

In this particular case, Google announced that AI technology it had developed was able to predict, with 70% accuracy, the risk of a cardiovascular event for patients over a five-year period, only 2% inferior to tests currently in use.

The AI works not by analysing blood samples but instead by examining images of the retinas of patients.

Global Cardiology Summit

Novartis targets specific patient population with strong Ilaris Phase 3 data

Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific subgroup of the trial’s patient population – a subgroup which the Swiss drugmaker is now looking to target with the drug.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches